Drug intelligence / Profile preview

Bondlido

Development stage: Approved
Lead developer: MEDRx
Modality: Small Molecules
Administration: Topical

Overview

Bondlido (MRX-5LBT) is a lidocaine topical patch developed by MEDRx Group in collaboration with D. Western Therapeutics Institute. It utilizes the proprietary Ionic Liquid Transdermal System (ILTS) technology, which leverages ionic liquid expertise to improve drug solubility and skin permeability while ensuring firm adhesion and reduced skin irritation. The active ingredient, lidocaine, is a small molecule local anesthetic that blocks voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses to provide relief from neuropathic pain. Bondlido was approved by the FDA in September 2025 for the treatment of post-herpetic neuralgia in adults. Each patch contains 200mg of lidocaine in a drug-in-adhesive delivery system.

Brand names: Bondlido
Other names: lidocaine

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Bondlido.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bondlido.